Toggle navigation
About Us
Overview
Management Team
Press Room
Careers
Contact us
Healthcare Professionals
Overview
Licenses and Certifications
Publications
Billing Information
Investors
Patients
Overview
Breast Cancer
Metastatic Cancer
Glossary
Billing Information
Make a Payment
Products
Order
Physician Portal
Order a Test
Press Room
1
2
3
4
Prospective Study Shows that Therapy Guided by Biotheranostics’ CancerTYPE ID® Molecular Test Improves Survival in Cancer of Unknown Primary Patients
Biotheranostics Adds Chief Commercial Officer & VP of Corporate Development
Biotheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer
Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by Biotheranostics’ CancerTYPE ID®
Biotheranostics’ CancerTYPE ID® Shows High Accuracy in a Multi-Site Validation Study and Improved Performance Compared with the Standard of Care in Metastatic Tumor Diagnosis
1
2
3
4